As prostate cancer is an androgen-dependent tumor, androgen deprivation therapy (ADT) and inhibition of the androgen receptor signaling pathway are the main endocrinologic treatments for patients with metastatic prostate cancer (4). The gene discussed is AR; the disease is prostate carcinoma.